Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Project # Project Title Research Focus Area Research Program Administering IC Institution(s) Investigator(s) Location(s) Year Awarded
1R01DA059376-01
Social Safety Net Programs as Interventions to Reduce Opioid-Related Harms in Reproductive-Age Women New Strategies to Prevent and Treat Opioid Addiction Preventing Opioid Use Disorder NIDA COLUMBIA UNIVERSITY HEALTH SCIENCES MARTINS, SILVIA SABOIA New York, NY 2023
NOFO Title: HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional)
NOFO Number: RFA-DA-23-051
Summary:

Social safety net programs and Medicaid that provide basic necessities such as shelter, health care, and food to people with low incomes are particularly important for women parents who use drugs. This project will examine the separate and combined impact of state social safety net program eligibility and administration on opioid-related behavioral outcomes for women parents experiencing poverty. Findings from this research will provide actionable recommendations for changes to these programs that may promote health and well-being for these women.

1K01DA059641-01
Adapting and Implementing a Chronic Disease Self-Management Program for Primary Care Patients with Opioid Use Disorder and Serious Mental Illness Cross-Cutting Research Training the Next Generation of Researchers in HEAL NIDA UNIVERSITY OF UTAH SIANTZ, ELIZABETH Salt Lake City, UT 2023
NOFO Title: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required) 
NOFO Number: PAS-22-206
Summary:

Many people with opioid use disorder (OUD) also have a serious mental illness and other chronic conditions, which can be difficult for individuals and primary care providers to manage. A chronic disease self-management program is an established health care model in which peers help to educate patients about their condition(s) and build problem-solving skills to manage their health. Such programs have been effective in other populations and settings, but they have not been adapted for primary care patients who have OUD and SMI. This project will adapt and test a chronic disease self-management program for this population to understand its feasibility, acceptability, impact, and how best to put such programs into place widely in primary care settings.

1R61DA059948-01
Workforce and System Change to Treat Adolescent Opioid Use Disorder Within Integrated Pediatric Primary Care Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS HULVERSHORN, LESLIE A (contact); AALSMA, MATTHEW; ADAMS, ZACHARY WILLIAM Indianapolis, IN 2023
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053
Summary:

The overdose crisis has expanded rapidly among adolescent populations in recent years, largely due to illicit substances containing lethal amounts of the highly potent synthetic opioid fentanyl. However, a provider shortage limits access to effective treatment for adolescents with opioid use disorder and other substance use disorders (SUD). Although primary care is a promising setting for expanding delivery of SUD treatment to adolescents, many primary care providers lack the training, resources, and support systems to deliver these services confidently and effectively. This project will leverage a large-scale rollout of integrated behavioral health care in a statewide health system. The research will test whether embedding behavioral health specialists into primary care visits, introducing case management and electronic clinical decision support tools, and reducing stigma will increase delivery of SUD treatment to adolescents.

1R61DA059895-01
Promoting Retention in Opioid Treatment among Women Experiencing Intimate Partner Violence: A Novel Stepped Care Model Targeting PTSD Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA YALE UNIVERSITY SULLIVAN, TAMI P (contact); EDELMAN, E JENNIFER; JOHNSON, DAWN M New Haven, CT 2023
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053
Summary:

Women with opioid use disorder (OUD) are disproportionately impacted by physical, sexual, and psychological intimate partner violence and posttraumatic stress disorder (PTSD). Yet, treatment approaches that address all these conditions together in OUD treatment settings are lacking. To address this gap, this project will evaluate delivery of two evidence-based interventions to address PTSD (Present-Centered Therapy+ and Helping to Overcome PTSD through Empowerment) for women seeking OUD treatment who have experienced intimate partner violence. It will also determine if integrated treatment can help retain the women in medication treatment for OUD.

1UG3DA058544-01A1
Antibody-based therapy for fentanyl-related opioid use disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA MCLEAN HOSPITAL DESAI, RAJEEV INDRAJIT (contact); BREMER, PAUL T Belmont, MA 2023
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1RF1NS135580-01
Validation of Prenatal Rabbit Hypoxia Ischemia as a Model of Cerebral Palsy-Induced Pain Preclinical and Translational Research in Pain Management Development and Optimization of Non-Addictive Therapies to Treat Pain NINDS UNIVERSITY OF RHODE ISLAND QUINLAN, KATHARINA ANN (contact); DETLOFF, MEGAN R Kingston, RI 2023
NOFO Title: HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-070
Summary:

Cerebral palsy (CP), the leading cause of childhood disabilities in the United States, refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination. The experience of pain is one of the most common, poorly understood, and inadequately treated conditions in CP, impairing health and quality of life for both patients and caregivers. To understand why pain and motor dysfunction occur together, a model that accurately replicates both is needed. This project will validate an established, rabbit model of CP motor dysfunction for use in studying and developing effective treatments for CP-associated pain.

1R01DE033322-01
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach Novel Therapeutic Options for Opioid Use Disorder and Overdose Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders NIDCR UNIVERSITY OF PITTSBURGH AT PITTSBURGH ROY, PAYEL JHOOM (contact); BUTLER, ANNE MOBLEY Pittsburgh, PA 2023
NOFO Title: HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DE-23-015
Summary:

Recently, concerns have been voiced that medications to treat opioid use disorder (OUD) may contribute to dental problems, including cavities and tooth loss. These concerns may contribute to barriers preventing use of these medications. A better understanding of the effects of these medications on oral complications is critical. This project will use national databases to link dental, medical, and pharmacy claims data for Medicaid- or commercially-insured new users of various medications for OUD to determine and compare oral health outcomes. The project will also examine the perspectives and experiences of people with OUD on oral health.

2SB1NS119103-04
Novel non-narcotic analgesic for acute and chronic pain Cross-Cutting Research Small Business Programs NINDS SOUTH RAMPART PHARMA, LLC NAISMITH, ROBERT New Orleans, LA 2023
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069
4UH3NS123964-02
Disease Modifying Analgesia with CA8 Gene Therapy Preclinical and Translational Research in Pain Management Development and Optimization of Non-Addictive Therapies to Treat Pain NINDS UNIVERSITY OF MIAMI SCHOOL OF MEDICINE LEVITT, ROY C Coral Gables, FL 2023
NOFO Title: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-21-010
1R01DA059469-01
Investigating Mechanisms Underpinning Outcomes in People on Opioid Agonist Treatment for OUD: Disentangling Sleep and Circadian Rhythm Influences on Craving and Emotion Regulation New Strategies to Prevent and Treat Opioid Addiction Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery NIDA EMMA PENDLETON BRADLEY HOSPITAL CARSKADON, MARY A (contact); MCGEARY, JOHN E; RICH, JOSIAH D Providence, RI 2023
NOFO Title: HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-23-059
Summary:

Sleep and circadian rhythms are understudied risk factors for opioid use disorder (OUD) and its treatment. Opioids affect sleep quality in a way that can inhibit recovery. The two most effective medications for OUD also cause sleep problems. This project will increase understanding about underlying circadian and behavioral mechanisms, such as changes in craving and/or the ability to regulate emotions, that link poor sleep with suboptimal opioid treatment response outcomes.

1RM1DA059395-01
HEALing Measurement Center: Enhancing Opioid Use Disorder Recovery Through Measurement Based Care Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA UNIVERSITY OF PITTSBURGH AT PITTSBURGH CLOUTIER, RENEE M (contact); ALDRIDGE, ARNIE PAUL; PRINGLE, JANICE L; SCOTT, KELLI Pittsburgh, PA 2023
NOFO Title: HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-046
Summary:

This project will enhance the measurement, quality, and equity of care delivered in 20 community opioid treatment programs in Pennsylvania by co-designing and implementing measurement-based care tools and systems. The research will inform future use of measurement-based care for opioid treatment in partnership with key stakeholders, as well as explore alternative avenues improving health outcomes, including helping patients remain in treatment.

1R61DA059947-01
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES ZIELINSKI, MELISSA JEAN (contact); ZALLER, NICKOLAS D Little Rock, AR 2023
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053
Summary:

Many people in jail have both opioid use disorder (OUD) and posttraumatic stress disorder (PTSD). Among people with OUD released from jail, only few engage in treatment and medication therapy once they are back in the community, and opioid overdose is a leading cause of death in this population. This project will test whether identifying and initiating treatment of PTSD in people receiving OUD treatment in jail can increase these individuals’ likelihood of starting and staying in medication treatment after release and thus reduce overdose risk.

1R01DA059422-01
Validation of a Virtual Still Face Procedure and Deep Learning Algorithms to Assess Infant Emotion Regulation and Infant-Caregiver Interactions in the Wild Enhanced Outcomes for Infants and Children Exposed to Opioids Virtual Assessments to Understand Developmental Trajectories of Substance Use Exposure NIDA UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN MCELWAIN, NANCY L (contact); HASEGAWA-JOHNSON, MARK ALLAN Champaign, IL 2023
NOFO Title: HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-23-050
Summary:

Both an infant’s ability to regulate their emotions and infant-parent interactions are critical to healthy brain and behavioral development. Accurate assessment of these factors for research in laboratory settings is technically difficult and burdensome for participants. Next-generation methods that can be used at home, including wearable sensors and machine learning approaches, promise to make it easier to assess infants with prenatal substance exposures. This project will use remote sensing technologies and machine learning to characterize dynamic real-time infant emotion regulation and infant-caregiver interactions throughout the day and in the home.

1RM1DE033491-01
Endosomal Mechanisms Signaling Oral Cancer Pain Preclinical and Translational Research in Pain Management Integrated Basic and Clinical Team-Based Research in Pain NIDCR NEW YORK UNIVERSITY SCHMIDT, BRIAN L (contact); BUNNETT, NIGEL W; KHANNA, RAJESH; LEONG, KAM W; YE, YI New York, NY 2023
NOFO Title: HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)
NOFO Number: RFA-NS-22-069
Summary:

Human oral cancer is associated with significant chronic pain, and a comprehensive understanding of the biology and mechanisms underlying this chronic pain is critical for developing better pain management strategies. This project will determine molecular characteristics, including a specific signaling system (endosomal GPCR kinase), associated with chronic oral cancer pain, using tissue samples obtained from patients with this condition. The findings will then be used to inform studies in animal models of human oral cancer pain to enhance understanding how endosomal GPCR kinase contributes to human oral cancer pain.

1K99AT012658-01
A Role for Peripheral NAAA-Regulated Lipid Signaling in the Control of Hyperalgesic Priming Cross-Cutting Research Training the Next Generation of Researchers in HEAL NCCIH UNIVERSITY OF CALIFORNIA-IRVINE FOTIO, YANNICK Irvine, CA 2023
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022
Summary:

Chronic pain remains a significant global heath challenge. Development of novel safe and effective treatments requires a deeper understanding of the molecular and cellular mechanisms that underlie the development of chronic pain. One protein that has been implicated in controlling the transition from acute to chronic pain is N-acylethanolamine acid amidase (NAAA). This project will evaluate how NAAA controls pain susceptibility after an acute insult and how this affects the emergence of chronic pain.

1UG3NS131785-01A1
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain Clinical Research in Pain Management Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions NINDS CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE - CWRU SAYEGH, RONY ROGER (contact); ROTROFF, DANIEL Cleveland, OH 2023
NOFO Title: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-22-050
Summary:

Cataract surgery is commonly performed in older adults; however, some patients subsequently experience chronic eye pain that is difficult to treat. One promising approach that is effective in some, but not all, patients uses the patient's own serum (a component of blood) as eye drops. This project seeks to identify markers that can help predict which patients will respond to serum treatment and monitor their progress. Using advanced technology and data analysis to evaluate patient histories, questionnaires, and different genetic and other molecular characteristics in the eyes and serum it aims to identify potential markers that can then be tested in a clinical study.

1R43HL167661-01A1
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions Cross-Cutting Research Small Business Programs NHLBI OPALGENIX, INC. PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR Indianapolis, IN 2023
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011
1R01DA059473-01
Sleep and Circadian Rhythm Phenotypes and Mechanisms Associated With Opioid Use Disorder Treatment Outcomes New Strategies to Prevent and Treat Opioid Addiction Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery NIDA JOHNS HOPKINS UNIVERSITY HUHN, ANDREW S (contact); RABINOWITZ, JILL ALEXANDRA Baltimore, MD 2023
NOFO Title: HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-23-059
Summary:

Chronic opioid use has well known effects on sleep quality, including disordered breathing during sleep and other abnormalities related to circadian rhythms. However, little is known about the relationship between sleep-related symptoms and non-medical opioid use among individuals being treated for opioid use disorder. This longitudinal study aims to identify biological pathways that may account for these associations. The research will first determine associations of sleep and proxy measures of circadian rhythms with non-medical opioid use. Second, they will investigate emotional processes associated with sleep/circadian symptoms and opioid treatment outcomes.

1R61DA059892-01
Data-Driven Approaches for Opioid Use Disorder Treatment, Recovery, and Overdose Prevention in Rural Communities via Mobile Health Clinics and Peer Support Services Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA CLEMSON UNIVERSITY RENNERT, LIOR (contact); LITWIN, ALAIN HARRIS Clemson, SC 2023
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053
Summary:

Although medication-based treatment for opioid use disorder (OUD) can effectively reduce overdose risk and improve health outcomes, most people discontinue treatment too soon. Peer support specialists, who are individuals with direct experience with a substance use disorder, can offer social support to help individuals with OUD overcome barriers to treatment and recovery. This project will develop, deliver, and evaluate an innovative peer support specialist intervention to help individuals begin and stay in a treatment program. The research will focus on rural populations and underserved communities, using a dynamic modeling framework to prioritize at-risk communities for treatment offered through mobile health clinics.

1R61DA059897-01
Testing a Video and Text Messaging Intervention to Reduce PTSD and Opioid Misuse Among Sexual Violence Survivors Translation of Research to Practice for the Treatment of Opioid Addiction Optimizing the Quality, Reach, and Impact of Addiction Services NIDA UNIVERSITY OF WISCONSIN-MADISON WALSH, KATIE L Madison, WI 2023
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053
Summary:

People who survive sexual violence are at increased risk for posttraumatic stress disorder (PTSD) and opioid misuse. Emergency departments are often the first, and in some cases only, contact with the medical care system for survivors of sexual violence. This makes them a suitable setting to initiate interventions to address the risk of PTSD and opioid misuse in these individuals. This project will develop and test a brief, low-cost video and text message intervention that can be initiated in the emergency department to prevent onset or escalation of PTSD and opioid misuse among people who survive sexual violence.

1UG3DA059414-01
Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals with Co-Occurring Internalizing Disorders New Strategies to Prevent and Treat Opioid Addiction Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions NIDA UNIVERSITY OF MINNESOTA ANKER, JUSTIN JACK (contact); RINEHART, LINDA Minneapolis, MN 2023
NOFO Title: HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-049
Summary:

People who have anxiety and/or depression are particularly susceptible to misusing opioids to avoid negative emotional states. This project aims to develop and test a fully autonomous (no-human operator) cognitive behavioral therapy-based digital therapeutic for people with co-occurring opioid use disorder and anxiety or depression. The goal is to specifically target compulsive opioid use motivated by the relief of unpleasant emotions. The researchers will modify an existing digital therapeutic and test its efficacy in this patient population.

1RF1NS134549-01
Validation of a New Large-Pore Channel as a Novel Target for Neuropathic Pain Preclinical and Translational Research in Pain Management Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain NINDS JOHNS HOPKINS UNIVERSITY QIU, ZHAOZHU (contact); GUAN, YUN Baltimore, MD 2023
NOFO Title: HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-034
Summary:

Activation of immune cells (microglia) in the central nervous system and neuroinflammation have emerged as key drivers of neuropathic pain. These processes can be triggered by release of ATP, the compound that provides energy to many biochemical reactions. The source and mechanism of ATP release are poorly understood but could be targets of novel treatment approaches for neuropathic pain. This project will use genetic, pharmacological, and electrophysiological approaches to determine whether a large pore channel called Swell 1 that spans the cell membrane is the source of ATP release and resulting neuropathic pain and thus could be a treatment target.

1R21DE033319-01
Oral Complications From Sublingual Buprenorphine Treatment: A Prospective Cohort Study Novel Therapeutic Options for Opioid Use Disorder and Overdose Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders NIDCR BRIGHAM AND WOMEN'S HOSPITAL SUZUKI, JOJI Boston, MA 2023
NOFO Title: HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R21 Clinical Trial Not Allowed)
NOFO Number: RFA-DE-23-016
Summary:

Buprenorphine is used for treatment of opioid use disorder (OUD), and patients often take it for many years by slowly dissolving it in the mouth. In 2022, the U.S. Food and Drug Administration warned about possible oral complications from buprenorphine use, including tooth decay, oral infections, and tooth loss. However, this warning was largely based on small studies with no comparison group and no assessment of other risk factors such as limited dental care. This project will follow two groups of individuals with OUD who take either sublingual buprenorphine or methadone, to compare their oral health and understand barriers and facilitators of dental care. The results will be used to plan an intervention for preventing and treating oral diseases in this patient group.

1UG3NS135168-01
IMPACT: Integrative Mindfulness-Based Predictive Approach for Chronic low back pain Treatment Clinical Research in Pain Management Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions NINDS WORCESTER POLYTECHNIC INSTITUTE KING, JEAN A (contact); AGU, EMMANUEL; MORONE, NATALIA E Worcester, MA 2023
NOFO Title: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-22-050
Summary:

Chronic low back pain affects millions of people in the United States, resulting in high medical costs and lost productivity. New opioid-free treatments are needed to help people with chronic low back pain, but not all people respond equally to a given approach. IMPACT aims to use machine learning to analyze data such as physical activity, sleep, emotions, and pain levels and identify markers that can help predict how effective a mindfulness-based treatment approach (Mindfulness-Based Stress Reduction) can be for people with chronic low back pain.

4R33NS113258-02
Multi-Omic Biomarkers for Neuropathic Pain Secondary to Chemotherapy Clinical Research in Pain Management Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions NINDS CLEVELAND CLINIC LERNER COM-CWRU ROTROFF, DANIEL (contact); FOSS, JOSEPH F; JOHNSON, KENWARD B Cleveland, OH 2023
NOFO Title: Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-NS-18-041